Literature DB >> 9708620

Mycophenolate mofetil therapy for lupus nephritis refractory to intravenous cyclophosphamide.

D Glicklich1, A Acharya.   

Abstract

Intravenous (i.v.) cyclophosphamide has been the treatment of choice for diffuse proliferative glomerulonephritis (DPGN) in patients with systemic lupus erythematosus (SLE). However, there is little guidance in the medical literature about what to do when this therapy fails. Mycophenolate mofetil (MMF), a new immunosuppressive agent, has been used successfully in patients with solid organ transplants and rheumatoid arthritis. We report two patients with diffuse proliferative glomerulonephritis who responded favorably to MMF therapy after i.v. cyclophosphamide failed.

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9708620     DOI： 10.1053/ajkd.1998.v32.pm9708620

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN： 0272-6386            Impact factor:   8.860


  15 in total

1.  Pancreatitis and duodenitis from sarcoidosis: successful therapy with mycophenolate mofetil.

Authors:  Andrew S O'Connor; Farhad Navab; Michael J Germain; Jonathan K Freeman; Jeffrey G Mulhern; Michael H O'Shea; George S Lipkowitz; Robert L Madden; Gregory L Braden
Journal:  Dig Dis Sci       Date:  2003-11       Impact factor: 3.199

2.  Defining the role of mycophenolate mofetil in the treatment of proliferative lupus nephritis.

Authors:  Oliver Lenz; Alessia Fornoni; Gabriel Contreras
Journal:  Drugs       Date:  2005       Impact factor: 9.546

3.  Mycophenolate mofetil is effective in reducing lupus glomerulonephritis proteinuria.

Authors:  Eduardo F Borba; Lissiane K Guedes; Romy B Christmann; Camille P Figueiredo; Célio R Gonçalves; Eloisa Bonfá
Journal:  Rheumatol Int       Date:  2006-05-31       Impact factor: 2.631

4.  Pharmacokinetics of mycophenolate mofetil for autoimmune disease in children.

Authors:  Guido Filler; Miriam Hansen; Claire LeBlanc; Nathalie Lepage; Doris Franke; Ingrid Mai; Janusz Feber
Journal:  Pediatr Nephrol       Date:  2003-04-08       Impact factor: 3.714

5.  [Revision of the recommendations of the Commission on Pharmacotherapy of the German Society for Rheumatology. Comment on the use of mycophenolic acid for systemic lupus erythematosus].

Authors:  R Fischer-Betz; F Hiepe
Journal:  Z Rheumatol       Date:  2007-02       Impact factor: 1.372

6.  Inosine monophosphate dehydrogenase (IMPDH) inhibition in vitro suppresses lymphocyte proliferation and the production of immunoglobulins, autoantibodies and cytokines in splenocytes from MRLlpr/lpr mice.

Authors:  C A Jonsson; H Carlsten
Journal:  Clin Exp Immunol       Date:  2001-06       Impact factor: 4.330

7.  ESRD from lupus nephritis in the United States, 1995-2010.

Authors:  Donal J Sexton; Scott Reule; Craig Solid; Shu-Cheng Chen; Allan J Collins; Robert N Foley
Journal:  Clin J Am Soc Nephrol       Date:  2014-12-22       Impact factor: 8.237

Review 8.  An update on the use of mycophenolate mofetil in lupus nephritis and other primary glomerular diseases.

Authors:  Alice S Appel; Gerald B Appel
Journal:  Nat Clin Pract Nephrol       Date:  2009-01-27

Review 9.  Treatment of lupus nephritis.

Authors:  Fayez F Hejaili; Louise M Moist; William F Clark
Journal:  Drugs       Date:  2003       Impact factor: 9.546

10.  Mycophenolate mofetil prevents a clinical relapse in patients with systemic lupus erythematosus at risk.

Authors:  M Bijl; G Horst; H Bootsma; P C Limburg; C G M Kallenberg
Journal:  Ann Rheum Dis       Date:  2003-06       Impact factor: 19.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.